ProCE Banner Activity

T2D and Overweight/Obesity Treatments—Clinical Evidence

Video

Watch this on-demand webcast to follow along as an expert reviews clinical evidence and guideline-based treatment recommendations for management of type 2 diabetes and obesity.

Released: June 26, 2024

Expiration: June 25, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the National AHEC Organization

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

National AHEC Organization

ProCE Banner

Disclosure

Primary Author

Donna H. Ryan, MD

Professor Emerita
Pennington Biomedical Research Center
Louisiana State University
New Orleans, Louisiana

Donna H. Ryan, MD: consultant/advisor/speaker: AbbVie, Altimune, Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot/Roche, Cin RX, Currax, eMedd, Epitomee, Fractl, Gila, Lilly, Nestle, Novo Nordisk, Pfizer, PPD, Regeneron, Scientific Intake, Structure Therapeutics, Source Bio, Tenvie, Zealand; individual publicly traded stock/stock options: Calibrate; other financial or material support: Cin RX.